RT Journal Article
SR Electronic
T1 Modeling the drivers of differential Typhoid Conjugate Vaccine (TCV) impact in Pakistan: force of infection and age-specific duration of protection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.30.24312839
DO 10.1101/2024.08.30.24312839
A1 Kraay, Alicia N.M.
A1 Yousafzai, Mohammad T.
A1 Qureshi, Sonia
A1 Gauld, Jillian
A1 Qamar, Farah N.
YR 2024
UL http://medrxiv.org/content/early/2024/08/31/2024.08.30.24312839.abstract
AB Background While trials have demonstrated high efficacy of typhoid conjugate vaccine (TCV), data on effectiveness are limited. We report initial impacts and predict future benefits of TCV from two provinces in Pakistan.Methods We used blood culture-confirmed typhoid cases from the Surveillance for Enteric Fever in Asia Project (SEAP) and Impact assessment of Typhoid conjugate vaccine following introduction in Routine Immunization Program of Pakistan (ITRIPP) to estimate the population-level impact of vaccination (2018-2023). We used regression models to estimate initial impacts and an agent-based model to predict future benefits.Findings In Sindh, typhoid incidence was higher and cases were younger compared with Punjab. TCV reduced incidence by 48.9% in Sindh (95% CI: 47.3-50.3%) and 66.2% in Punjab (95% CI: 64.7%, 67.6%) over the first 2 years after vaccine rollout but declined each year. In Sindh, waning was quicker and models predicted that population incidence would stabilize near pre-vaccine levels in 2024. An additional campaign could provide short-term, but not long-term, benefits. In contrast, in Punjab, incidence is projected to remain low for several years, and the standard vaccine program may be sufficient. However, follow up data from Punjab are needed to better characterize waning immunity.Interpretation TCV has reduced incidence in Pakistan, but protection varies by site. Standard vaccine policy may be sufficient to control incidence in settings with moderate transmission. However, in settings with particularly high incidence and/or short duration of protection, alternative strategies to reduce the force of infection may be needed.Funding Bill & Melinda Gates FoundationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill & Melinda Gates FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the National Bio-Ethics Committee of Pakistan gave ethical approval for these studiesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data in the present study are privileged, but interested researchers may contact the authors to discuss collaboration opportunities.